Rallybio (RLYB) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Rallybio Corporation  (NASDAQ: RLYB)


Rallybio's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Rallybio's ROA in the third quarter of 2026?
Rallybio Corporation achieved a return on average assets (ROA) of 34.21 % in its third quarter of 2026, this is above RLYB's average return on assets of -35.87%.
Rallybio Corporation assets over the 12 months ending in its third quarter of 2026 are valued at $78 million

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 27 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3319, from total ROA ranking in the second quarter of 2026 at 3945.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 43.28 % 93.47 % -6.56 % -8.38 % -14.62 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 27 46 -8 -9 -14
Return On Assets (TTM) 34.21 % 64.12 % -13.25 % -14.98 % -23.09 %
RLYB's Total Ranking # 3319 # 3945 # 3631 # 4267 # 4339
Total Assets (TTM) in million 97 100 54 62 68
Seq. Total Assets Change -2.86 % 83.19 % -12.51 % -7.97 % 31.17 %
Seq. Net Income Change - - - - -

RLYB's 5 Years Annual ROA >> Back to RLYB Management Effectiveness >> Compare RLYB ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 15
Sector # 28
Overall # 104

Return On Assets Statistics
High Average Low
64.51 %
-35.87 %
-69.33 %
(Jun 30 2026)   (Sep 30 2024)



  News about Rallybio Corporation Return on Assets ROA

Advancing the Frontiers of Fetal and Neonatal Alloimmune Thrombocytopenia Prevention Rallybios RLYB212 Clinical Tria...

Rallybio Corporation, a clinical-stage biotechnology company, has embarked on a transformative journey to address the challenges posed by fetal and neonatal alloimmune thrombocytopenia (FNAIT). This article provides insights into the recent initiation of a Phase 2 clinical trial for RLYB212, a novel monoclonal anti-HPA-1a antibody, alongside an epidemiological analysis highlighting the susceptibility of diverse populations to FNAIT. The implications of these developments for maternal and fetal health are profound, with the potential to revolutionize the management of alloimmunization risks in pregnant women.Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) is a serious condition that can arise when a pregnant woman develops antibodies against her fetus s platelets. The most common cause is the incompatibility of the human platelet antigen HPA-1a. Historically, management of FNAIT has been limited, leading to grave outcomes for affected neonates. Rallybio Corporation aims to close this therapeutic gap with RLYB212, a monoclonal antibody designed to mitigate the risks of maternal alloimmunization and subsequent FNAIT.



Financial Statements
Rallybio's Assets $ 97 million RLYB's Balance sheet
Rallybio's Income $ -3 million Quarterly RLYB's Income Statement
RLYB's Income by Division See RLYB's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -8.38 % -41.17 % -35.81 % -1.23 % -
Total Assets in million 62 68 116 180 182
Y / Y Net Income Change - - - - -
Net Income in million -9 -58 -75 -67 -26
Annual Return On Assets -14.42 % -85.02 % -64.55 % -37.04 % -14.52 %

RLYB's 5 Years Annual ROA >> Back to RLYB Management Effectiveness >> Compare RLYB ROA to its Competitors



More Return On Assets Ratios
RLYB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RLYB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RLYB's Competitors
Subscribers only: Roa for Rallybio's Suppliers
Subscribers only: Return On Assets for RLYB's Customers

You may also want to know
RLYB's Roi RLYB's Inventory Turnover Ratio RLYB's Growth Rates RLYB's Dividend Comparisons
RLYB's Profitability Ratios RLYB's Asset Turnover Ratio RLYB's Dividend Growth
RLYB's Roe RLYB's Valuation Ratios RLYB's Financial Strength Ratios RLYB's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Exelixis Inc   63.88 %
Rigel Pharmaceuticals Inc  59.56 %
Alnylam Pharmaceuticals Inc   46.08 %
Ironwood Pharmaceuticals inc   42.53 %
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %

Date modified: 2026-10-28T09:27:47+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.